Patterns and Differences in Lung Cancer Treatment - United States, 2015-2020.

IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Chest Pub Date : 2024-10-25 DOI:10.1016/j.chest.2024.10.033
Christine M Kava, David A Siegel, Jin Qin, Susan A Sabatino, Reda Wilson, Manxia Wu
{"title":"Patterns and Differences in Lung Cancer Treatment - United States, 2015-2020.","authors":"Christine M Kava, David A Siegel, Jin Qin, Susan A Sabatino, Reda Wilson, Manxia Wu","doi":"10.1016/j.chest.2024.10.033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment for lung cancer can improve prognosis, but 5-year survival remains low at 26%. An examination of treatment using data with higher population coverage, and among a broader number of treatment modalities and individual characteristics, would provide greater insight into differences in lung cancer treatment.</p><p><strong>Research question: </strong>Among adults diagnosed with lung cancer, how does reported receipt of lung cancer treatment differ by sociodemographic characteristics?</p><p><strong>Study design and methods: </strong>We used 2015-2020 National Program of Cancer Registry data covering 89% of the US population to describe first-course treatment among persons ages ≥20 years diagnosed with lung and bronchus cancer. We performed multivariable logistic regression to examine associations between sociodemographic characteristics and treatment received.</p><p><strong>Results: </strong>Among 1,068,155 people diagnosed with lung cancer, 22% received surgery, 41% received chemotherapy, 40% received radiation, 13% received immunotherapy, and 75% received at least one of the four treatments. People who were ages >45 years (odds ratio [OR] range=0.08-0.67); American Indian or Alaska Native (OR=0.82; 95% CI: 0.77-0.87), Black (OR=0.82; 95% CI: 0.81-0.84), or Hispanic (OR=0.80; 95% CI: 0.78-0.82); resided in a non-metropolitan county (OR=0.98; 0.96-0.99); resided in the bottom 25% (OR=0.80; 95% CI: 0.78-0.81) and middle 50% (OR=0.87; 95% CI: 0.86-0.88) of counties by economic status (considers unemployment rate, per capita market income, and poverty rate); and in the West US census region (OR=0.95; 95% CI: 0.94-0.97) had significantly lower odds of receiving at least one of the four treatments.</p><p><strong>Interpretation: </strong>Chemotherapy and radiation were the most common types of first-course treatment reported. Receipt of at least one of the four treatments examined was lower among several groups, including certain racial and ethnic groups and those residing in counties with lower economic status. Future studies might further identify and intervene upon factors underlying differences.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":null,"pages":null},"PeriodicalIF":9.5000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2024.10.033","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Treatment for lung cancer can improve prognosis, but 5-year survival remains low at 26%. An examination of treatment using data with higher population coverage, and among a broader number of treatment modalities and individual characteristics, would provide greater insight into differences in lung cancer treatment.

Research question: Among adults diagnosed with lung cancer, how does reported receipt of lung cancer treatment differ by sociodemographic characteristics?

Study design and methods: We used 2015-2020 National Program of Cancer Registry data covering 89% of the US population to describe first-course treatment among persons ages ≥20 years diagnosed with lung and bronchus cancer. We performed multivariable logistic regression to examine associations between sociodemographic characteristics and treatment received.

Results: Among 1,068,155 people diagnosed with lung cancer, 22% received surgery, 41% received chemotherapy, 40% received radiation, 13% received immunotherapy, and 75% received at least one of the four treatments. People who were ages >45 years (odds ratio [OR] range=0.08-0.67); American Indian or Alaska Native (OR=0.82; 95% CI: 0.77-0.87), Black (OR=0.82; 95% CI: 0.81-0.84), or Hispanic (OR=0.80; 95% CI: 0.78-0.82); resided in a non-metropolitan county (OR=0.98; 0.96-0.99); resided in the bottom 25% (OR=0.80; 95% CI: 0.78-0.81) and middle 50% (OR=0.87; 95% CI: 0.86-0.88) of counties by economic status (considers unemployment rate, per capita market income, and poverty rate); and in the West US census region (OR=0.95; 95% CI: 0.94-0.97) had significantly lower odds of receiving at least one of the four treatments.

Interpretation: Chemotherapy and radiation were the most common types of first-course treatment reported. Receipt of at least one of the four treatments examined was lower among several groups, including certain racial and ethnic groups and those residing in counties with lower economic status. Future studies might further identify and intervene upon factors underlying differences.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺癌治疗的模式和差异 - 美国,2015-2020 年。
背景:肺癌治疗可改善预后,但 5 年生存率仍然很低,仅为 26%。利用人口覆盖率更高的数据、更广泛的治疗方式和个人特征对治疗情况进行检查,将能更深入地了解肺癌治疗的差异:研究设计和方法:我们利用 2015-2020 年美国国家癌症登记计划数据(覆盖 89% 的美国人口)来描述年龄≥20 岁的肺癌和支气管癌确诊患者的首次治疗情况。我们进行了多变量逻辑回归,以研究社会人口特征与接受治疗之间的关联:在 1,068,155 名确诊为肺癌的患者中,22% 接受了手术治疗,41% 接受了化疗,40% 接受了放疗,13% 接受了免疫治疗,75% 接受了上述四种治疗中的至少一种。年龄大于45岁(几率比[OR]范围=0.08-0.67)、美国印第安人或阿拉斯加原住民(OR=0.82;95% CI:0.77-0.87)、黑人(OR=0.82;95% CI:0.81-0.84)或西班牙裔(OR=0.80;95% CI:0.78-0.82)、居住在非大城市县(OR=0.98;0.96-0.99)、居住在底层25%(OR=0.80;95% CI:0.78-0.81)和中等50%(OR=0.87;95% CI:0.86-0.88)的县域经济状况(考虑失业率、人均市场收入和贫困率);以及美国西部人口普查地区(OR=0.95;95% CI:0.94-0.97)的患者接受四种治疗中至少一种治疗的几率显著较低:化疗和放疗是所报告的最常见的首诊治疗类型。在一些群体中,包括某些种族和民族群体以及那些居住在经济地位较低县城的人,接受四种治疗中至少一种治疗的几率较低。未来的研究可能会进一步确定和干预造成差异的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
期刊最新文献
Association of Age at Smoking Initiation, Age at Smoking Cessation, and Lower Respiratory Mortality: Prospective Study of 500,000 Adults in the United States. Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment. Effective Behaviors of Leaders During Clinical Emergencies: A Qualitative Study of Followers' Perspectives. Framework for Research Gaps in Pediatric Ventilator Liberation. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1